Download PDF
Dtsch Med Wochenschr 2013; 138(16): 842-847
DOI: 10.1055/s-0033-1343117
Arzneimittel & Pharmakotherapie | Review article
Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York

Später Natriumstrom und Kalzium-Overload: Ursachen verstehen und adäquat behandeln

Late sodium current and calcium overload – Pathogenesis and adequate treatment
C. Jacobshagen
1   Abteilung Kardiologie und Pneumologie, Herzzentrum, Georg-August-Universität Göttingen
› Author Affiliations
Further Information

Publication History

26 November 2012

07 March 2013

Publication Date:
15 April 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

koronare Herzkrankheit - stabile Angina pectoris - später Natriumstrom - Kalzium-Overload - Ranolazin - diastolische Herzinsuffizienz - Vorhofflimmern

Keywords

coronary artery disease - stable angina pectoris - late sodium current - calcium overload - diastolic heart failure - atrial fibrillation
 

  • Literatur

  • 1 Bangalore S, Steg G, Deedwania P et al. Beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308: 1340-1349
    CrossrefPubMedGoogle Scholar
  • 2 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK – Langfassung. Kapitel 11: Modul Medikamentöse Therapie. 2. Auflage. Version 1.0, 2011. Available from: http://www.khk.versorgungsleitlinien.de
    Google Scholar
  • 3 Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291: 309-316
    CrossrefPubMedGoogle Scholar
  • 4 Chaitman BR, Skettino SL, Parker JO et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43: 1375-1382
    CrossrefPubMedGoogle Scholar
  • 5 Figueredo VM, Pressman GS, Romero-Corral A et al. Improvement in Left Ventricular Systolic and Diastolic Performance During Ranolazine Treatment in Patients With Stable Angina. J Cardiovasc Pharmacol Ther 2011; 16: 168-172
    CrossrefPubMedGoogle Scholar
  • 6 Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-816
    CrossrefPubMedGoogle Scholar
  • 7 Fraser H, Belardinelli L, Wang L et al. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 2006; 41: 1031-1038
    CrossrefPubMedGoogle Scholar
  • 8 Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-497
    CrossrefPubMedGoogle Scholar
  • 9 Hayashida W, van Eyll C, Rousseau MF et al. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994; 8: 741-747
    CrossrefPubMedGoogle Scholar
  • 10 Hueb W, Lopes N, Gersh BJ et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010; 122: 949-957
    CrossrefPubMedGoogle Scholar
  • 11 Jacobshagen C, Belardinelli L, Hasenfuss G et al. Ranolazine for the Treatment of Heart Failure With Preserved Ejection Fraction: Background, Aims, and Design of the RALI-DHF Study. Clin Cardiol 2011; 34: 426-432
    CrossrefPubMedGoogle Scholar
  • 12 Ju YK, Saint DA, Gage PW. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol 1996; 497: 337-347
    PubMedGoogle Scholar
  • 13 Maier LS, Layug B, Kawatowska-Prokopczuk E et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction. The RALI-DHF proof-of-concept study. J Am Coll Cardiol HF 2013; 1: 115-122
    PubMedGoogle Scholar
  • 14 Maltsev VA, Silverman N, Sabbah HN et al. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail 2007; 9: 219-227
    CrossrefPubMedGoogle Scholar
  • 15 Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2011; 108: 673-676
    CrossrefPubMedGoogle Scholar
  • 16 Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007; 297: 1775-1783
    CrossrefPubMedGoogle Scholar
  • 17 Morrow DA, Scirica BM, Sabatine MS et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 2010; 55: 1189-1196
    CrossrefPubMedGoogle Scholar
  • 18 Murdock DK, Kersten M, Kaliebe J et al. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J 2009; 9: 260-267
    PubMedGoogle Scholar
  • 19 Neef S, Dybkova N, Sossalla S et al. CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res 2010; 106: 1134-1144
    CrossrefPubMedGoogle Scholar
  • 20 Patel MR, Peterson ED, Dai D et al. Low diagnostic yield of elective coronary angiography. N Engl J Med 2010; 362: 886-895
    CrossrefPubMedGoogle Scholar
  • 21 Rousseau MF, Pouleur H, Cocco G et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005; 95: 311-316
    CrossrefPubMedGoogle Scholar
  • 22 Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906
    CrossrefPubMedGoogle Scholar
  • 23 Scirica BM, Morrow DA, Hod H et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116: 1647-1652
    CrossrefPubMedGoogle Scholar
  • 24 Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001; 3: 351-357
    CrossrefPubMedGoogle Scholar
  • 25 Song Y, Shryock JC, Belardinelli L. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol 2008; 294: H2031-H2039
    CrossrefPubMedGoogle Scholar
  • 26 Sossalla S, Kallmeyer B, Wagner S et al. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 2010; 55: 2330-2342
    CrossrefPubMedGoogle Scholar
  • 27 Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther 2012; 133: 311-323
    CrossrefPubMedGoogle Scholar
  • 28 Sossalla S, Wagner S, Rasenack EC et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts – role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008; 45: 32-43
    CrossrefPubMedGoogle Scholar
  • 29 Stone PH, Chaitman BR, Stocke K et al. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol 2010; 56: 934-942
    CrossrefPubMedGoogle Scholar
  • 30 Stone PH, Gratsiansky NA et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48: 566-575
    CrossrefPubMedGoogle Scholar
  • 31 Tagarakis GI, Aidonidis I, Daskalopoulou SS et al. Effect of Ranolazine in Preventing Postoperative Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery. Curr Vasc Pharmacol 2012; Nov 7. [Epub ahead of print]
    PubMedGoogle Scholar
  • 32 Tani M, Neely JR. Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Possible involvement of H+-Na+ and Na+-Ca2+ exchange. Circ Res 1989; 65: 1045-1056
    CrossrefPubMedGoogle Scholar
  • 33 The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction. N Engl J Med 1989; 321: 406-412
    CrossrefPubMedGoogle Scholar
  • 34 Valdivia CR, Chu WW, Pu J et al. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol 2005; 38: 475-483
    CrossrefPubMedGoogle Scholar
  • 35 Valdivia CR, Chu WW, Pu J et al. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol 2005; 38: 475-483
    CrossrefPubMedGoogle Scholar
  • 36 von Mering GO, Arant CB, Wessel TR et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 722-725
    CrossrefPubMedGoogle Scholar
  • 37 Weintraub WS, Spertus JA, Kolm P et al. Effect of PCI on Quality of Life in Patients with Stable Coronary Disease. N Engl J Med 2008; 359: 677-687
    CrossrefPubMedGoogle Scholar
  • 38 Wilson SR, Scirica BM, Braunwald E et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009; 53: 1510-1516
    CrossrefPubMedGoogle Scholar
  • 39 Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988; 260: 2088-2093
    CrossrefPubMedGoogle Scholar
  • 40 Zhao G, Walsh E, Shryock J et al. Anti-Adrenergic and Hemodynamic Effects of Ranolazine in Conscious Dogs Zhao, Anti-Adrenergic Effect of Ranolazine. J Cardiovasc Pharmacol 2011; Feb 21. [Epub ahead of print]
    PubMedGoogle Scholar